SCHEMBL32682848

SCHEMBL32682848

CC(C)(C)OC(=O)N1CCN(C(=O)CCC(=O)ON2C(=O)CCC2=O)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DDB1 Q16531 1/20 0.49
▸ CRBN Q96SW2 1/20 0.49
▸ DTYMK P23919 2/20 0.45
▸ EPHX2 P34913 1/20 0.42
▸ USP2 O75604 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ CHRM2 P08172 1/20 0.39
▸ CHRM4 P08173 1/20 0.39
▸ CHRM1 P11229 1/20 0.39
▸ CHRM3 P20309 1/20 0.39
▸ PARP1 P09874 1/20 0.38
▸ PDE3B Q13370 1/20 0.38
▸ PDE3A Q14432 1/20 0.38
▸ GPR4 P46093 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ MAPT P10636 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ THRB P10828 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12995623 0.83 USP2 (0.49) DDB1CRBNEPHX2USP2SMN1; SMN2
SCHEMBL12092238 0.82 TACR1 (0.36) DDB1CRBNUSP2MEN1KMT2A
SCHEMBL8740492 0.81 STING1 (0.34) DDB1CRBNEPHX2CHRM2CHRM1
SCHEMBL19698164 0.79 CYP2D6 (0.37) DDB1CRBNEPHX2MEN1KMT2A
SCHEMBL23119464 0.79 EPHX2 (0.50) DDB1CRBNDTYMKEPHX2USP2
SCHEMBL9014148 0.78 KDM4E (0.46) DDB1CRBNMAPTKDM4ETHRB
SCHEMBL16330527 0.77 ALDH1A1 (0.39) MAPTALDH1A1LMNA
SCHEMBL19703782 0.77 NPC1 (0.53) SMN1; SMN2CHRM2CHRM4CHRM1CHRM3
SCHEMBL22400349 0.77 NFKB1 (0.35) DDB1CRBNKMT2AALDH1A1
SCHEMBL21664525 0.76 POLB (0.55) USP2SMN1; SMN2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070935-A1 BISPHOSPHONATE LIPIDS, LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME, MINERAL TISSUE-ADSORBED COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF UNIV PENNSYLVANIA (US) 2026-03-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260070935-A1 BISPHOSPHONATE LIPIDS, LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME, MINERAL TISSUE-ADSORBED COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF BCR, PHOSPHO1, BST2 DDB1 1481/4885CRBN 1590/4885DTYMK 1812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback